PLX-038 is under clinical development by ProLynx and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase II drugs for Small-Cell Lung Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PLX-038’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PLX-038 is under development for the treatment of refractory or relapsed solid tumors including squamous non-small cell lung cancer, colorectal cancer, small cell lung cancer, triple-negative breast cancer (TNBC), ovarian cancer, peritoneal cancer, fallopian tube cancer and gastric cancer. It is administered through the intravenous route. It is a small molecule, long-acting, pegylated form of SN38. SN-38 is the active metabolite of the anti-cancer agent irinotecan (CPT-11). It acts by targeting topoisomerase 1. The drug candidate is developed based on the disruptive drug delivery system (DDS) technology.
ProLynx is a biotechnology company that has developed advanced linker technologies and a facile, transformative platform for controlled release of therapeutics from circulating and fixed macromolecular conjugates. The company is headquartered in San Francisco, California, the US.
For a complete picture of PLX-038’s drug-specific PTSR and LoA scores, buy the report here.